$LQDA

Schundler Russell sold $390K of LQDA

Schundler Russell (General Counsel) sold 13,692 shares of Liquidia Corp (LQDA) at $28.48 ($0.39M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schundler Russell
Published Oct 14, 2026, 12:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate price impact.

02

Market read

Primary relevance is to investors monitoring insider activity; broader market impact is minimal.

03

What to watch

The 10b5-1 plan pre‑arranges sales, reducing the informational content of the transaction.

Relevance 3/10Novelty 3/10Timing: after-hours

Background

SEC Form 4 filings disclose insider transactions. Liquidia Corp (LQDA) is a clinical‑stage biotech focused on mRNA therapeutics.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

General Counsel Schundler Russell sold 13,692 shares for $389,948 via a 10b5-1 plan, reducing his holdings to 602,841 shares.

Expected impact

potential modest pressure as the market prices in the insider sell

Evidence & confidence

The sale size is modest relative to float and disclosed via a pre‑arranged plan, limiting predictive power.

Market effects

Minimal impact on the biotech sector; insider sales are routine and unlikely to shift sector sentiment.

No regional effect; the filing is specific to Liquidia Corp.

Limited relevance beyond investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity move, not a negative signal; price may remain stable.

Key entities

  • Liquidia Corp

    US‑listed biotech company (ticker LQDA).

  • Schundler Russell

    General Counsel of Liquidia Corp, insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.